Stearic acid
|
Basic information |
| Metabolite name | Stearic acid |
 | HMDB0000827 |
 |
C01530 |
 |
5281 |
| Synonyms | octadecanoic acid; |
| No. of studies | 42 |
|
Basic information |
| Metabolite name | Stearic acid |
| HMDB0000827 |
|
C01530 |
|
5281 |
| Synonyms | octadecanoic acid; |
| No. of studies | 42 |
|
Relationship between Stearic acid and depression (count: 42) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M001 | Type4 | remitted group vs. non-remitted group | Plasma | Human | Up |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M020 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Down |
| Study M029 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M029 | Type2 | CUMS + BHD group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M064 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M064 | Type2 | CUMS + fluoxetine group vs. CUMS group | Cecum | Sprague-Dawley rat | Up |
| Study M071 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Up |
| Study M1045 | Type1 | anxiety and depression group vs. control group | Plasma | Human | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + low dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M110 | Type1 | SD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M113 | Type2 | CUMS + exercise group vs. CUMS group | Serum | Wistar rat | Up |
| Study M1143 | Type2 | MDD group, after 12-week escitalopram treatment vs. baseline | Plasma | Human | Down |
| Study M116 | Type3 | LY group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Serum | Kunming mouse | Down |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M510 | Type1 | HSD group vs. control group | Urine | Human | Up |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M610 | Type1 | CUMS group vs. control group | Heart | Sprague-Dawley rat | Down |
| Study M610 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M610 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M611 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Heart | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Liver | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Kidney | Sprague-Dawley rat | Unknown |
| Study M635 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M635 | Type2 | depression group, after vs. before Xiaoyaosan treatment | Plasma | Human | Down |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M671 | Type1 | CUMS group vs. control group | Striatum | Sprague-Dawley rat | Up |
| Study M685 | Type1 | SDS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M749 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Up |
| Study M771 | Type1 | CSDS group vs. control group | Faece | C57BL/6J mouse | Up |
| Study M846 | Type1 | postpartum depression model group vs. control group | Hippocampus | BALB/c mouse | Down |
| Study M867 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M890 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M935 | Type4 | chronic social isolation + tianeptine group vs. chronic social isolation + tianeptine resilient group | Hippocampus | Wistar rat | Up |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |